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Abstract
Drug‐induced liver injury (DILI) should be considered in all patients with recent
elevation of liver tests without obvious etiology and normal hepatobiliary imaging.
There is currently no biomarker that is helpful in diagnosis which relies on clinical
and laboratory findings. Diagnosis is dependent on temporal relationship with a
recently started drug or herbal and dietary supplement and elevated liver tests with
exclusion of competing etiologies. The implicated agent should be discontinued and
the patient should be observed closely. This is particularly important in patients
with jaundice who have approximately 10% risk of liver related mortality and/or
need for liver transplantation. There is no specific therapy for DILI which is only
symptomatic such as for itching. Patients with jaundice and coagulopathy usually
require hospitalization.
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INTRODUCTION
Idiosyncratic drug‐induced liver injury (DILI) is a relatively rare adverse
reaction and an important differential diagnosis among patients who
present with elevated liver tests of unknown etiology.1 In the vast
majority of cases, the liver injury is of acute nature.2 The reason for
development of DILI in a small proportion of patients taking the same
drug is largely unknown. Risk in susceptible individuals have mostly
been associated with specific human leucocyte antigen (HLA) types
associated with reactive metabolites which can serve as haptens.3,4
Thus, immunologic pathogenesis has been suggested. Liver injury due
to TNF‐alpha and check point inhibitors has beennamed indirect injury
postulated to be due to immune dysregulation.5,6
Idiosyncratic DILI and direct liver injury due to paracetamol are
the most common causes of acute liver failure in both Europe and the
United States7,8 and accounted for 3%–5% of patients hospitalized
for jaundice in the United States9 and 11% among patients with
ALT > 500 IU in Iceland similar to the proportion of patients with
viral hepatitis.10 Incidence of DILI has been found to be 14–19 cases
per 100,000 inhabitants.1,11 The proportion of patients treated with
amoxicillin‐clavulanate (AC), a common cause of DILI was found to
occur in 1:2350 patients treated but in only 1:133 patients taking
azathioprine and 1:148 patients receiving infliximab.1 Understanding
of the natural history, phenotypic presentation and pathogenesis has
increased considerably during the last two decades.3,4 However,
there is a medical need to improve the diagnostic accuracy of DILI
and there is still no specific therapy that can alter the natural history
of DILI. Thus, there are large areas of uncertainty in DILI. The aim of
the current review was to present an update on the diagnostic
approach, natural history, and current management of DILI. Two case
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reports are presented to illustrate the morbidity that can be asso-
ciated with DILI and challenges in management.
Case Report 1 A sixty‐year‐old woman presented with
nausea and jaundice with three times upper limit of normal
(ULN) in ALP and ALT 5xULN, bilirubin peaked after 3 weeks
at 208 (normal <25). Hepatobiliary imaging was normal. DILI
due to AC and azithromycin was suspected. Viral serologies
negative. The itching was very severe making it difficult to
wear clothes, bathing, being touched. She was treated with
cholestyramine for itching with a partial response. She
recovered clinically and biochemically after approximately
3 months.
HOW TO DIAGNOSE DILI?
Major advances in the diagnosis in most liver diseases have taken
place during the last 2–3 decades, such as in viral hepatitis with
PCR technology, routine use of different autoantibodies, identifica-
tion of hepatitis E, phosphatidylethanol (B‐Peth) for suspicion of
alcoholic liver disease and gene mutations in patients with iron
overload to name a few. Unfortunately, progress in the diagnosis of
DILI has only been indirect by improving exclusion of other
potential causes of elevated liver tests. Currently, there is no bio-
logical marker for DILI although novel biomarkers are tested in
International multicenter studies. The most important in the diag-
nostic process is to include DILI among the differential diagnoses.
The types and phenotypes and DILI have been a subject of a recent
review showing a large variation in biochemical, immunological,
functional, and even structural changes in the liver and the bilary
system.3
The question is in which patients with elevated liver tests DILI
should be expected? This relies heavily on the clinical and biochem-
ical context. The vast majority of patients present acutely.3,5,9,10
Chronic hepatitis has though been reported to occur after long term
treatment of nitrofurantoin and minocycline.12,13
The diagnosis is sometimes obvious as is illustrated in case report
1. The patient presents with acutely with symptoms of liver disease
such as itching and nausea and has recently been treated with a drug
well recognized for leading to DILI such as AC but has also been
treated with another drug azithromycin which also has well docu-
mented potential causing liver injury.14 Other differential diagnoses
quickly ruled out, DILI by clinical judgment seems obvious but it is
impossible to state which drugs is responsible. Both drugs should be
contraindicated in the future. However, if a patient is suspected of
DILI and only one drug is known to cause DILI, other drugs should
not be discontinued as illustrated in case report 2. Apart from viral
hepatitis that needs to be ruled out in patients with acute hepato-
cellular liver injury, autoimmune hepatitis is the main differential
diagnosis in a patient with a clear ALT predominance over ALP. If
liver injury is accompanied by moderate and severe abdominal pain
this argues against DILI and it should be remembered that
choledocholithiasis can lead to acute hepatocellular injury at the first
presentation and MRCP is often needed to illustrate this.10 When the
patient presents subacutely, the diagnosis of DILI is more difficult as
demonstrated in Case report 2.
Case Report 2 A 76‐year‐old woman referred for painless
jaundice with normal hepatobiliary CT and MRCP. Her ALP
was 444 (normal 105), ALT 197 (<45), bilirubin 62 (<25).
Liver tests were normal 3 months earlier when she was put
on aspirin 75 mg, clopidogrel 75 mg, and atorvastatin 40 mg.
Atorvastatin was discontinued but other drugs continued.
Liver tests normalized after a few weeks and she recovered
clinically. Atorvastatin induced liver injury was considered a
very likely cause of jaundice.
Case 2 illustrates the importance of the documentation of liver
injury associated with different agents. Atorvastatin has been asso-
ciated with more than 50 published cases with causality assessment
according to categorization of drugs included in LiverTox (https://
www.ncbi.nlm.nih.gov/books/NBK547852/), therefore belonging to
Category A, with drugs with established potential of causing liver
injury.15 However, only 14 cases of clopidogrel induced liver injury
have been published, although it has been in use for almost 25 years
(marketed in the United States 1997). Atorvastatin has been mostly
associated with cholestatic type of injury and in a study from Sweden
the median duration of atorvastatin prior to diagnosis of liver injury
was 4 months.16 Atorvastatin induced liver injury is rare, occurring in
approximately one out of 3700 users according to one study.5 The
latency and the biochemical signature can be helpful to judge which
drug is the most likely culprit as some important drugs should not be
discontinued, such as clopidogrel in patients with coronary stents to
avoid stent occlusion.
Currently, the most important elements in the diagnostic process
are latency of onset, results of dechallenge, exclusion of other causes
and information about the previous hepatotoxicity of the drug. The
most commonly used causality assessment method, Roussel Uclaf
Causality Assessment Method (RUCAM)17 is rarely used in clinical
practice but has been widely used in published papers on patients
with DILI.1,4,18–20 RUCAM is a good checklist for the most important
elements that needs to be taken into consideration when confronted
with a suspected DILI. However, RUCAM has until now not been
updated since it was published in 1993 and it has probably not stood
the test of time.17 RUCAM has recently been validated by the use of
clinical and biochemical data from the Spanish18 and DILIN21 pro-
spective registries. RUCAM has been updated with the aims to clarify
operating instructions and increase reproducibility and a computer-
ized version or RECAM (revised electronic (version) of causality
assessment method) has been created.22 The so‐called Expert
opinion method has been used by the DILIN investigators, who score
the likelihood of DILI in patient suspected of that diagnosis.21 The
problem is if the opinion of the “experts” differ and when a consensus
is reached as has been pointed out, this carries the risk of overruling
an insightful minority opinion.20 The most important things that need
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to be taken into consideration in terms of the diagnosis of DILI is
illustrated in Table 1.
In Table 2, the most commonly implicated agents in three pro-
spective studies are demonstrated.
NATURAL HISTORY, INCLUDING OUTCOMES OF
DILI
Once DILI is diagnosed on good clinical grounds and the implicated
agent is discontinued, the vast majority of patients recover clinically
and biochemically. This is true also for patients who present with
drug‐induced jaundice but as could be expected their prognosis is
worse than patients who do not have jaundice. The late Hyman
Zimmerman found that drug‐induced jaundice was associated with
10% mortality, called the Hy's rule2,3 which has been validated.18,19,21
If jaundice is accompanied by coagulopathy the condition is more
severe as in other types of liver disease. The worst‐case scenario, is
the development of acute liver injury, worsening jaundice and
coagulopathy, and then encephalopathy.8 In contrast with paraceta-
mol induced liver failure that develops very acutely, the development
of liver failure due to idiosyncratic DILI is mostly subacute, that is,
develops slower and has a poor transplant free survival.7,8 In a study
from the United States, Reuben et al. reported that among patients
with acute liver failure due to DILI, transplant free survival was only
23% and 40% underwent a liver transplant. Remarkably similar
results were reported from Sweden.7
From large cohorts of DILI patients mortality of 5%–10% has
been reported mostly from acute liver failure in those who presented
with jaundice and coagulopathy.18–20 In a recent update of more than
800 patients recruited in the Spanish hepatotoxicity registry, liver
related mortality was more frequent in hepatocellular damage, aged
TAB L E 1 Diagnostic algorithm that can be useful in the diagnostic evaluation and management of DILI
Abbreviation: DILI, drug‐induced liver injury.
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>65 years and in patients with underlying liver disease.23 Most data
on prognosis from the DILI registries are from within
6 months.18,19,21 Hayashi et al. reviewed all fatalities that occurred
within 2 years of the DILI.24 Among 1089 DILIN patients, 7.6% of
fatalities were due to liver injury, partially or primarily within 2 years
of follow‐up and 9.5% died among those with jaundice.24 Overall 68/
86 (82%) died or underwent liver transplantation as a direct conse-
quence of liver injury, majority 59/68 (87%) within 6 months whereas
the remaining 13% developed a more chronic injury and died of liver
failure within the 2 years observation period.24 DILI was associated
with a late mortality, directly and/or indirectly in approximately 1%
of the total cohort.24 This is in line with long‐term follow‐up of pa-
tients who presented with drug‐induced jaundice in Sweden, where
1.5% developed chronic DILI.25 Thus, chronic liver injury can occur
and can in rare instances be associated with liver related morbidity
and mortality.24,25
CURRENT MANAGEMENT
The most important step in management is to discontinue the
implicated agent to decrease risk of further liver damage. Patients
with DILI and comitant jaundice should be followed closely with
repeated measurements of liver tests and those with significant
coagulopathy (INR > 1.5) often need hospitalization.
There is limited data to suggest that the natural course of DILI
can be changed by available therapeutic agents. However,
N‐Acetylcysteine (NAC) should be used in acute liver failure due to
idiosyncratic DILI, particularly in early stages. This is based on a NAC‐
trial in patients with non‐paracetamol induced acute liver failure that
induced by DILI in a large proportion of patients.26 Transplant free
survival was found to be 52% of those randomized to NAC versus
only 27% for those who were on placebo. Given the lack of other
therapies and the safety of NAC it is reasonable to treat drug‐
induced ALF with significant coagulopathy (INR > 1.5) with NAC
before they develop overt hepatic encephalopathy. Patients who
present with autoimmune features who have been on drugs with well
documented autoimmune like biochemical picture, that is, with
hepatocellular pattern, positive autoantibodies and/or elevated IgG
and do not recover clinically and biochemically after withdrawal of
the offending drug, should be treated with corticosteroids as patients
with genuine autoimmune hepatitis (AIH).5,13,27 Long standing in-
crease in ALT after four infusions of Infliximab in 40 year old woman
is demonstrated in Figure 1, prompt response to corticosteroids and
liver histology prior to steroid therapy.
Drugs that typically induce AIH‐like picture are nitrofurantoin,
minocycline, methyl‐dopa, hydralazine, and infliximab. Patients show
prompt resolution of liver tests within days of corticosteroid therapy
as shown in Figure 1.5,12,13 Similarly, patients with check point
inhibitors, can develop liver injury requiring corticosteroids.27
A meta‐analysis of randomized clinical trials for prevention and
treatment of idiosyncratic DILI has recently been published.28
Overall, 22 RCTs were included: 12 on prevention and 10 in man-
agement. Silymarin (8 studies), bicyclol (n = 4), isoglycyrrhizinate
(n = 3), N‐acetylcysteine (n = 3), traditional Chinese medicines
(n = 2), tiopronin and L‐carnitine were used in the treatment arm, but
the control arm received placebo or standard medical care. A large
heterogeneity was observed in terms of inclusion criteria and
methodologic quality. The interventional studies performed demon-
strated limited efficacy of specific interventions. It was concluded
that International research collaboration is needed to design a trial in
DILI with proper therapeutic endpoints. However, it is not clear
which therapeutic intervention should be tried but there is a medical
need to try to improve the prognosis of patients with DILI. DILI
patients often develop severe morbidity, with jaundice, severe leth-
argy and itching for weeks or months and at the current time,
symptomatic treatment and cholestyramine for itching are the only
options to help these patients.
TAB L E 2 The most common implicated agents causing DILI in three prospective studies on DILI
Spanish registry (n = 843), Reference 24 DILIN (n = 899), Reference 21 Icelandic study (n = 96), Reference 1
Amoxicillin‐clavulanate (22%) Amoxicillin‐clavulanate (10%) Amoxicillin‐clavulanate (22%)
Anti‐tuberculosis (4.5%) Isoniazid (5.3%) Diclofenac (6.3%)
Ibuprofen (3%) Nitrofurantoin (4.7%) Nitrofurantoin (4%)
Flutamide (2.6%) Sulfam‐trimeth (3.4%) Azathioprine (4%)
Atorvastatin (1.9%) Minocycline (3.1%) Infliximab (4%)
Diclofenac (1.8%) Cefazolin (2.2%) Isotretinoin (3%)
Ticopidine (1.4%) Azithromycin (2%) Atorvastatin (2%)
Azathioprine (1.3%) Ciprofloxacin (1.8%) Doxycyline (2%)
Fluvastatin (1.3%) Levofloxacin (1.4%) Imatinib (1%)
Simvastatin (1.3%) Diclofenac (1.3%) Isoniazid (1%)
HDS (3.4%) HDS (16.1%) HDS (16%)
Abbreviations: DILI, drug‐induced liver injury; HDS, herbal and dietary supplements; Sulfam‐trimeth, sulfamethoxazole‐trimethoprim.
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AREAS OF UNCERTINTY AND FUTURE PROSPECTS
The diagnosis of DILI has been called the acchiles heel of the study of
DILI. Although computerized version or RECAM is under way and will
be available in the public domain soon, there is still a lack of biological
marker that can be helpful to distinguish DILI from other liver dis-
eases. International research projects are ongoing to validate novel
biomarkers for diagnosis and also biomarkers that can be valuable to
predict prognosis. Other problematic clinical aspect in DILI is the lack
of specific intervention that can affect the natural history of the liver
injury and randomized controlled trials are needed to establish effi-
cacy on clinical outcomes. Given the increase in immunomodulatory
treatment of cancer with accompanying indirect DILI, controlled
trials are needed to compare different doses of corticosteroids as the
ultra‐high doses recommended by the oncological societies are not
without side effects.
CONCLUSIONS
In recent years, the understanding of DILI has increased considerably.
However, further research is needed to improve the diagnostic stra-
tegies. At the current time the most important first step in the diag-
nostic process is to suspect the diagnosis, follow the patient closely,
concomitantly exclude competing etiologies, recognize typical signa-
tures of the most common agents leading to DILI and to find out how
well documented hepatotoxicity of the implicated agent is. This will
enable us to assess a patient with suspected DILI and help us make up
our mind about how likely it is that the patient suffers from DILI.
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